



GENEMEDI

Innovative Solution
for Therapeutics & Diagnostics Industry



Biologics Solution Product Catalogue 2025 for Gene & Cell Therapy (GCT)

Gene Therapy

AAV Purification Resin&Kit
AAV Titration Kits (ELISA)
INDKan™ Industry-Used AAV Vector System
GM Multi-Serotype AAV Vector System
GM Promise™ ORF Viral Library

Cell Therapy

CAR-Analytical Tools-Anti-FMC63/G4Sn Linker/VHH
CDEx Flow Cytometry Antibodies
Immunomagnetic Beads (IMB) for Cell Isolation

About GeneMedi

GeneMedi specializes in creating superior antibody, protein, and vector-based bioproducts, revolutionizing diagnostics and biologics solutions.



At GeneMedi, innovation, product integrity, and scalable solutions form the cornerstone of our mission to advance the field of diagnostics and biologics. Our portfolio of antibodies, proteins, and vector-derived products is built on a foundation of unparalleled expertise in the following areas:

Innovative Antigen Design and Robust Assay Development

Our strategic focus on biomarkers and target analysis enables the creation of highly specific antigens and the development of robust assays, ensuring our products achieve superior performance in clinical and research settings.



Streamlined Molecular Discovery with Emphasis on Stability

Rapid Protein & Antibody Identification: Our proprietary platforms, **TAURUS™** for accelerated antibody discovery and **LIBRA™** for AI-driven protein evolution, are designed to identify and optimize molecules with optimal stability and functionality.

Cutting-Edge AAV & GCT Discoveries: The **G-NEXT™** platform is our answer to the industry's need for innovative AAV vectors, offering improved stability, efficiency, and safety for groundbreaking gene therapy approaches.



Scalable Production and Uncompromising Quality

High-Volume Protein & Antibody Manufacturing: Our facilities are equipped to handle large-scale production of up to 1000L per batch, ensuring high levels of purity and stability through stringent quality controls.

Advanced Vector Manufacturing Capabilities: In GeneMedi Vector Core (**GVC**), with a focus on AAV, Lentivirus, and VLP production up to 200L per batch, we employ sophisticated purification techniques to guarantee vector efficacy and integrity.



Comprehensive Solutions for Diverse Application Needs

Diagnostics: Our diagnostic solutions leverage **CLIA**, **LFA**, **ELISA** and unique **POCT** platforms for comprehensive assay validation and clinical sample consistency, setting new standards in diagnostic accuracy.

Biologics: We specialize in the development of industrial solutions in up/downstream for therapeutic antibodies, AAV gene therapy, and Cell therapy technologies, ensuring our products and solutions can improve specificity, potency, and safety in the therapeutic industry.



GeneMedi (GM) is dedicated to delivering innovative and scalable biotechnological solutions, driving forward the fields of diagnostics and therapeutics with confidence and expertise. Contact with GM to reach your reliable industrial partner.

Table Of Contents

Part 1 Solution for Gene Therapy Development

AAV-Analytical Tools:

PURPROX™ AAVEasy Purification Spin Column

PURPROX™ AAVPure Affinity Resins

TRUEX™ AAV Titration Kits (ELISA)

Vector:

INDKan™ Industry-Used AAV Vector System GM

Multi-Serotype AAV Vector System GM

Promise™ ORF Viral Library

Part 2 Solution for Cell Therapy Development

SOLIDEX™ -TAGEx CAR-Analytical Tools: Anti-FMC63, Anti-G4S linker, Anti-VHH (Naked/PE/APC/FITC)

SOLIDEX™ -CDEx Flow Cytometry Antibodies (Naked/PE/APC/FITC)

SOLIDEX™ -ISOExT Immunocytes Cell Isolation Immunomagnetic Beads(IMB)

CAR-X Good-Validated Premade Lenti-CAR Particles

Part 3 Platform & Service

GVC QbD Platform for Viral vectors Processes Development & Manufacturing

G-NEXT™ Novel AAV discovery and rational evolution platform

Part 1 Solution for Gene Therapy Development

PURPROX™ AAVEasy Purification Spin Column



Easy Spin-Purification
Ultracentrifugation-FREE



Serotype All-in-One
AAV1~9, recombinant & chimeric Capsid



High Recovery Rate
>90% AAV recovery



Easy-Handling
within 30 min




High throughput
Dozens of samples purified at once


Equilibration Buffer Loading Buffer Elution Buffer

Purification Process

• AAV • Other particles




Equilibration




Loading



Binding



Washing




Elution

Case Study

AAV5 Purification by PURPROX™ AAVEasy


Handling Time: 29 min

Recovery Rate: 95.43%



PURPROX™ AAVPure Affinity Resins

AAV-based gene therapy: Promising future



Problems in AAV-based gene therapy

- Off-targeting
- Naturalizing antibody in patents
- Small genome
- Extremely expensive

Only 3 companies offer commercial available AAV affinity resin


Company	
ThermoFisher-AAVX	➔
Citiva-AVB	
Repligen-AVIPure	
	● One of the reason for High-cost CMC in AAV drugs

PURPROX™-AAVPure


AAV High affinity resin with low-cost and high efficiency

PURPROX™ AAVPure Affinity Resins


Synthesis of VHH anti-AAV



Multi AAV serotype binding




Multi AAV serotype purification




Similar with the golden standard resin

Case Study: AAV5 Purification with GM AAVPure Affinity Resin



Patents submitted: 202411155372.1;202411027377.6

TRUEX™ AAV Titration kit (ELISA)



★ HRP

Serotype	Linear Range
AAV9	8.23E6-2.00E9 capsids/ml
AAV8	1.38E7-8.82E8 capsids/ml
AAV5	8.22E6-2.00E9 capsids/ml



More Sensitive



Easy-Handling ELISA




Wider Linear



Batches-stable


AAV9

AAV9 standard	OD450
2.00E+09	3.2912
6.67E+08	1.6383
2.22E+08	0.7381
7.41E+07	0.3181
2.47E+07	0.186
8.23E+06	0.1183
0	0.0936




AAV8

AAV8 standard	OD450
8.82E+08	2.1997
4.41E+08	1.2879
2.21E+08	0.7443
1.10E+08	0.3593
5.51E+07	0.2119
2.76E+07	0.1193
1.38E+07	0.104
0	0.0383



AAV5

AAV5 standard	OD450
2.00E+09	2.874
6.66E+08	1.542
2.22E+08	0.698
7.38E+07	0.296
2.47E+07	0.139
8.22E+06	0.090
0	0.053



GM Multi-Serotype AAV Vector System INDKan™

Industry-Used AAV Vector System

Product list of AAV Rep-Cap plasmids

Cat.No	Products Name (For	Cat.No	Products Name
P-RC01	AAV1 Rep-Cap Plasmid	P-RC01-Kan	AAV1 Rep-Cap Plasmid (Kan resistance)
P-RC02	AAV2 Rep-Cap Plasmid	P-RC02-Kan	AAV2 Rep-Cap Plasmid (Kan resistance)
P-RC03	AAV2 variant(Y444F) Rep-Cap plasmid	P-RC03-Kan	AAV2 variant(Y444F) Rep-Cap Plasmid (Kan resistance)
P-RC04	AAV2 variant (Y272F, Y444F, Y500F, Y730F) Rep-Cap plasmid	P-RC04-Kan	AAV2 variant (Y272F, Y444F, Y500F, Y730F) Rep-Cap Plasmid (Kan resistance)
P-RC05	AAV2 variant (Y444F, Y730F, Y500F, Y272F, Y704F, Y252F) Rep-Cap plasmid	P-RC05-Kan	AAV2 variant (Y444F, Y730F, Y500F, Y272F, Y704F, Y252F) Rep-Cap Plasmid (Kan resistance)
P-RC06	AAV2 variant (AAV2.7m8) Rep-Cap plasmid	P-RC06-Kan	AAV2 variant (AAV2.7m8) Rep-Cap Plasmid (Kan resistance)
P-RC07	AAV5 Rep-Cap Plasmid	P-RC07-Kan	AAV5 Rep-Cap Plasmid (Kan resistance)
P-RC08	AAV6 Rep-Cap Plasmid	P-RC08-Kan	AAV6 Rep-Cap Plasmid (Kan resistance)
P-RC09	AAV8 Rep-Cap Plasmid	P-RC09-Kan	AAV8 Rep-Cap Plasmid (Kan resistance)
P-RC10	AAV8-1m Rep-Cap plasmid	P-RC10-Kan	AAV8-1m Rep-Cap Plasmid (Kan resistance)
P-RC11	AAV8-2m Rep-Cap plasmid	P-RC11-Kan	AAV8-2m Rep-Cap Plasmid (Kan resistance)
P-RC12	AAV8 variant (Y733F, Y447F, Y275) Rep-Cap plasmid	P-RC12-Kan	AAV8 variant (Y733F, Y447F, Y275) Rep-Cap Plasmid (Kan resistance)
P-RC13	AAV9 Rep-Cap Plasmid	P-RC13-Kan	AAV9 Rep-Cap Plasmid (Kan resistance)
P-RC14	AAV-Rh.10 Rep-Cap Plasmid	P-RC14-Kan	AAV-Rh.10 Rep-Cap Plasmid (Kan resistance)
P-RC15	AAV-DJ Rep-Cap Plasmid	P-RC15-Kan	AAV-DJ Rep-Cap Plasmid (Kan resistance)
P-RC16	AAV-DJ/8 Rep-Cap Plasmid	P-RC16-Kan	AAV-DJ/8 Rep-Cap Plasmid (Kan resistance)
P-RC17	AAV-Retro (Retrograde) Rep-Cap plasmid	P-RC17-Kan	AAV-Retro (Retrograde) Rep-Cap Plasmid (Kan resistance)
P-RC18	AAV9-PHP.B Rep-Cap Plasmid	P-RC18-Kan	AAV9-PHP.B Rep-Cap Plasmid (Kan resistance)
P-RC20	AAV9-PHP.eB Rep-Cap plasmid	P-RC20-Kan	AAV9-PHP.eB Rep-Cap Plasmid (Kan resistance)
P-RC21	AAV9-PHP.S Rep-Cap plasmid	P-RC21-Kan	AAV9-PHP.S Rep-Cap Plasmid (Kan resistance)
P-RC22	AAV-BR1 Rep-Cap plasmid	P-RC22-Kan	AAV-BR1 Rep-Cap Plasmid (Kan resistance)
P-RC24	AAV-2i8 Rep-Cap plasmid	P-RC24-Kan	AAV-2i8 Rep-Cap Plasmid (Kan resistance)
P-RC25	AAV-SIG Rep-Cap plasmid	P-RC25-Kan	AAV-SIG Rep-Cap Plasmid (Kan resistance)
P-RC26	AAV-VEC Rep-Cap plasmid	P-RC26-Kan	AAV-VEC Rep-Cap Plasmid (Kan resistance)
P-RC27	AAV4 Rep-Cap plasmid	P-RC27-Kan	AAV4 Rep-Cap Plasmid (Kan resistance)
P-RC28	AAV6.2 Rep-Cap plasmid	P-RC28-Kan	AAV6.2 Rep-Cap Plasmid (Kan resistance)
P-RC29	AAV6.2FF Rep-Cap plasmid	P-RC29-Kan	AAV6.2FF Rep-Cap Plasmid (Kan resistance)
P-RC30	MyoAAV 1A Rep-Cap plasmid	P-RC30-Kan	MyoAAV 1A Rep-Cap Plasmid (Kan resistance)
P-RC31	MyoAAV 2A Rep-Cap plasmid	P-RC31-Kan	MyoAAV 2A Rep-Cap Plasmid (Kan resistance)
P-RC32	MyoAAV 3A Rep-Cap plasmid	P-RC32-Kan	MyoAAV 3A Rep-Cap Plasmid (Kan resistance)
P-RC33	MyoAAV 4A Rep-Cap plasmid	P-RC33-Kan	MyoAAV 4A Rep-Cap Plasmid (Kan resistance)
P-RC34	MyoAAV 4E Rep-Cap plasmid	P-RC34-Kan	MyoAAV 4E Rep-Cap Plasmid (Kan resistance)

GM Multi-Serotype AAV Vector System

INDKan™ Industry-Used AAV Vector System

Product list of AAV expression plasmids (Amp and Kanamycin)

Cat.No	Products Name	Cat.No	Products Name
P-AAVV-B01	pGMAAV-CMV-MCS-3flag-T2A-ZsGreen	P-AAVV-B01-Kan	pGMAAV-CMV-MCS-3flag-T2A-ZsGreen (Kan resistance)
P-AAVV-B02	pGMAAV-CMV-MCS-3flag-P2A-Zsgreen	P-AAVV-B02-Kan	pGMAAV-CMV-MCS-3flag-P2A-Zsgreen (Kan resistance)
P-AAVV-B03	pGMAAV-CMV-MCS-3flag-EF1-ZsGreen	P-AAVV-B03-Kan	pGMAAV-CMV-MCS-3flag-EF1-ZsGreen (Kan resistance)
P-AAVV-B04	pGMAAV-CAG-MCS-T2A-ZsGreen	P-AAVV-B04-Kan	pGMAAV-CAG-MCS-T2A-ZsGreen (Kan resistance)
P-AAVV-B05	pGMAAV-CAG-MCS-3flag-T2A-ZsGreen	P-AAVV-B05-Kan	pGMAAV-CAG-MCS-3flag-T2A-ZsGreen (Kan resistance)
P-AAVV-B06	pGMAAV-CAG-MCS-T2A-mCherry	P-AAVV-B06-Kan	pGMAAV-CAG-MCS-T2A-mCherry (Kan resistance)
P-AAVV-B07	pGMAAV-CAG-DIO-MCS-T2A-ZsGreen	P-AAVV-B07-Kan	pGMAAV-CAG-DIO-MCS-T2A-ZsGreen (Kan resistance)
P-AAVV-B08	pGMAAV-CAG-DIO-MCS-T2A-mCherry	P-AAVV-B08-Kan	pGMAAV-CAG-DIO-MCS-T2A-mCherry (Kan resistance)
P-AAVV-B09	pGMAAV-CMV-DIO-MCS-T2A-ZsGreen	P-AAVV-B09-Kan	pGMAAV-CMV-DIO-MCS-T2A-ZsGreen (Kan resistance)
P-AAVV-B10	pGMAAV-hSyn-DIO-MCS-ZsGreen	P-AAVV-B10-Kan	pGMAAV-hSyn-DIO-MCS-ZsGreen (Kan resistance)
P-AAVV-B11	pGMAAV-hSyn-DIO-MCS-mCherry	P-AAVV-B11-Kan	pGMAAV-hSyn-DIO-MCS-mCherry (Kan resistance)
P-AAVV-B12	pGMAAV-hSyn-MCS-T2A-ZsGreen	P-AAVV-B12-Kan	pGMAAV-hSyn-MCS-T2A-ZsGreen (Kan resistance)
P-AAVV-B13	pGMAAV-hSyn-MCS-T2A-mCherry	P-AAVV-B13-Kan	pGMAAV-hSyn-MCS-T2A-mCherry (Kan resistance)
P-AAVV-B14	pGMAAV-CamKII-MCS-T2A-ZsGreen	P-AAVV-B14-Kan	pGMAAV-CamKII-MCS-T2A-ZsGreen (Kan resistance)
P-AAVV-B15	pGMAAV-CamKII-MCS-T2A-mCherry	P-AAVV-B15-Kan	pGMAAV-CamKII-MCS-T2A-mCherry (Kan resistance)
P-AAVV-B16	pGMAAV-GFAP-MCS-T2A-EGFP	P-AAVV-B16-Kan	pGMAAV-GFAP-MCS-T2A-EGFP (Kan resistance)
P-AAVV-B17	pGMAAV-cTNT-MCS-ZsGreen	P-AAVV-B17-Kan	pGMAAV-cTNT-MCS-ZsGreen (Kan resistance)
P-AAVV-B18	pGMAAV-GFAP-EGFP	P-AAVV-B18-Kan	pGMAAV-GFAP-EGFP (Kan resistance)
P-AAVV-B19	pGMAAV-TBG-MCS-P2A-ZsGreen	P-AAVV-B19-Kan	pGMAAV-TBG-MCS-P2A-ZsGreen (Kan resistance)
P-AAVV-B20	pGMAAV-U6-MCS-CMV-mCherry	P-AAVV-B20-Kan	pGMAAV-U6-MCS-CMV-mCherry (Kan resistance)
P-AAVV-B21	pGMAAV-U6-MCS-CMV-EGFP	P-AAVV-B21-Kan	pGMAAV-U6-MCS-CMV-EGFP (Kan resistance)
P-AAVV-B22	pGMAAV-U6-MCS-WPRE	P-AAVV-B22-Kan	pGMAAV-U6-MCS-WPRE (Kan resistance)
P-AAVV-B23	pGMAAV-CMV-Sacas9-U6-gRNA	P-AAVV-B23-Kan	pGMAAV-CMV-Sacas9-U6-gRNA (Kan resistance)
P-AAVV-B24	pscAAV-U6-BB-chemeric-sgRNA	P-AAVV-B24-Kan	pscAAV-U6-BB-chemeric-sgRNA (Kan resistance)
P-AAVV-B25	pGMAAV-CMV-MCS-EF1-mCherry	P-AAVV-B25-Kan	pGMAAV-CMV-MCS-EF1-mCherry (Kan resistance)
P-AAVV-B26	pGMAAV-CMV-MCS-T2A-mCherry	P-AAVV-B26-Kan	pGMAAV-CMV-MCS-T2A-mCherry (Kan resistance)
P-AAVV-B27	pGMAAV-CMV-DIO-MCS	P-AAVV-B27-Kan	pGMAAV-CMV-DIO-MCS (Kan resistance)
P-AAVV-B28	pGMAAV-CMV-DIO-MCS-T2Am-ZsGreen	P-AAVV-B28-Kan	pGMAAV-CMV-DIO-MCS-T2Am-ZsGreen (Kan resistance)
P-AAVV-B29	pGMAAV-CMV-DIO-ZsGreen-MCS	P-AAVV-B29-Kan	pGMAAV-CMV-DIO-ZsGreen-MCS (Kan resistance)
P-AAVV-B30	pGMAAV-CAG-DIO-MCS	P-AAVV-B30-Kan	pGMAAV-CAG-DIO-MCS (Kan resistance)
P-AAVV-B31	pGMAAV-hSyn-MCS-T2Am-mCherry	P-AAVV-B31-Kan	pGMAAV-hSyn-MCS-T2Am-mCherry (Kan resistance)
P-AAVV-B32	pGMAAV-hSyn-ZsGreen	P-AAVV-B32-Kan	pGMAAV-hSyn-ZsGreen (Kan resistance)
P-AAVV-B33	pGMAAV-cTNT-MCS-P2A-EGFP	P-AAVV-B33-Kan	pGMAAV-cTNT-MCS-P2A-EGFP (Kan resistance)
P-AAVV-B34	pGMAAV-TBG-MCS-P2A-mCherry	P-AAVV-B34-Kan	pGMAAV-TBG-MCS-P2A-mCherry (Kan resistance)
P-AAVV-B35	pGMAAV-U6-MCS-CMV-LUCi	P-AAVV-B35-Kan	pGMAAV-U6-MCS-CMV-LUCi (Kan resistance)

GM Multi-Serotype AAV Vector System

INDKan™ Industry-Used AAV Vector System

Product list of AAV expression plasmids (Amp and Kanamycin)

Cat.No	Products Name	Cat.No	Products Name
P-AAVV-B36	pGMAAV-U6-MCS-CMV-ZsGreen	P-AAVV-B36-Kan	pGMAAV-U6-MCS-CMV-ZsGreen (Kan resistance)
P-AAVV-B37	pGMAAV-CTNT-MCS-CMV-ZsGreen	P-AAVV-B37-Kan	pGMAAV-CTNT-MCS-CMV-ZsGreen (Kan resistance)
P-AAVV-B38	pscAAV-U6-BB-sgRNA-CMV-mCherry-new	P-AAVV-B38-Kan	pscAAV-U6-BB-sgRNA-CMV-mCherry-new (Kan resistance)
P-AAVV-B39	pscAAV-U6-BB-sgRNA-CMV-EGFP-new	P-AAVV-B39-Kan	pscAAV-U6-BB-sgRNA-CMV-EGFP-new (Kan resistance)
P-AAVV-B40	pGMAAV-cre-ZsGreen	P-AAVV-B40-Kan	pGMAAV-cre-ZsGreen (Kan resistance)
P-AAVV-B41	pGMAAV-hSyn-cre	P-AAVV-B41-Kan	pGMAAV-hSyn-cre (Kan resistance)
P-AAVV-B42	pGMAAV-TBG-MCS-P2A-mCherry	P-AAVV-B42-Kan	pGMAAV-TBG-MCS-P2A-mCherry (Kan resistance)
P-AAVV-B43	pGMAAV-GFAP-MCS-P2A-mCherry	P-AAVV-B43-Kan	pGMAAV-GFAP-MCS-P2A-mCherry (Kan resistance)
P-AAVV-B44	pGMAAV-CAG-DIO-T2Am-EGFP	P-AAVV-B44-Kan	pGMAAV-CAG-DIO-T2Am-EGFP (Kan resistance)
P-AAVV-B45	pGMAAV-CMV-DIO-EGFP	P-AAVV-B45-Kan	pGMAAV-CMV-DIO-EGFP (Kan resistance)
P-AAVV-B46	pGMAAV-U6-MCS-CMV-luc(Δ EGFP)	P-AAVV-B46-Kan	pGMAAV-U6-MCS-CMV-luc(Δ EGFP) (Kan resistance)
P-AAVV-B47	pGMAAV-CMV-MCS-EF1-EGFP(Δ WPRE)	P-AAVV-B47-Kan	pGMAAV-CMV-MCS-EF1-EGFP(Δ WPRE) (Kan resistance)
P-AAVV-B48	pGMAAV-EF1-MCS-CMV-EGFP	P-AAVV-B48-Kan	pGMAAV-EF1-MCS-CMV-EGFP (Kan resistance)
P-AAVV-B49	pGMAAV-hCAG-MCS-P2A-ZsGreen	P-AAVV-B49-Kan	pGMAAV-hCAG-MCS-P2A-ZsGreen (Kan resistance)
P-AAVV-B50	pGMAAV-CMV-MCS-P2A-ZsGreen	P-AAVV-B50-Kan	pGMAAV-CMV-MCS-P2A-ZsGreen (Kan resistance)
P-AAVV-B51	pGMAAV-CMV-MCS-P2A-luc(Δ EGFP)	P-AAVV-B51-Kan	pGMAAV-CMV-MCS-P2A-luc(Δ EGFP) (Kan resistance)
P-AAVV-B52	pGMAAV-hSyn-MCS-T2Am-ZsGreen	P-AAVV-B52-Kan	pGMAAV-hSyn-MCS-T2Am-ZsGreen (Kan resistance)
P-AAVV-B53	pGMAAV-TNT-3flag-P2A-EGFP	P-AAVV-B53-Kan	pGMAAV-TNT-3flag-P2A-EGFP (Kan resistance)
P-AAVV-B55	pGMAAV-pGMAAV-cTNT-MCS	P-AAVV-B55-Kan	pGMAAV-pGMAAV-cTNT-MCS (Kan resistance)
P-AAVV-B56	pGMAAV-CMV-MCS-T2A-mcherry	P-AAVV-B56-Kan	pGMAAV-CMV-MCS-T2A-mcherry (Kan resistance)
P-AAVV-B57	pGMAAV-cTNT-MCS-3flag-P2A-EGFP	P-AAVV-B57-Kan	pGMAAV-cTNT-MCS-3flag-P2A-EGFP (Kan resistance)
P-AAVV-B58	pGMAAV-hSyn-cre	P-AAVV-B58-Kan	pGMAAV-hSyn-cre (Kan resistance)
P-AAVV-B59	pscAAV-U6-BB-sgRNA-PGK-EGFP	P-AAVV-B59-Kan	pscAAV-U6-BB-sgRNA-PGK-EGFP (Kan resistance)
P-AAVV-B60	pGMAAV-CMV-DIO-tdtomato	P-AAVV-B60-Kan	pGMAAV-CMV-DIO-tdtomato (Kan resistance)
P-AAVV-B61	pGMAAV-CAG-DIO-T2Am-tdtomato	P-AAVV-B61-Kan	pGMAAV-CAG-DIO-T2Am-tdtomato (Kan resistance)
P-AAVV-B62	pGMAAV-EF1a-DIO-FLPo-WPRE-hGHpA	P-AAVV-B62-Kan	pGMAAV-EF1a-DIO-FLPo-WPRE-hGHpA (Kan resistance)
P-AAVV-B63	pGMAAV-CAG-MCS (NO WPRE)	P-AAVV-B63-Kan	pGMAAV-CAG-MCS (NO WPRE) (Kan resistance)
P-AAVV-B64	pGMAAV-CAG-MCS-T2A-ZsGreen (NO WPRE)	P-AAVV-B64-Kan	pGMAAV-CAG-MCS-T2A-ZsGreen (NO WPRE) (Kan resistance)
P-AAVV-B65	pGMAAV-CMV-MCS (NO WPRE)	P-AAVV-B65-Kan	pGMAAV-CMV-MCS (NO WPRE) (Kan resistance)
P-AAVV-B66	pGMAAV-CMV-MCS-T2A-ZsGreen (NO WPRE)	P-AAVV-B66-Kan	pGMAAV-CMV-MCS-T2A-ZsGreen (NO WPRE) (Kan resistance)
P-AAVV-B67	pGMAAV-TBG-MCS-CMV-ZsGreen	P-AAVV-B67-Kan	pGMAAV-TBG-MCS-CMV-ZsGreen (Kan resistance)
P-AAVV-B68	pGMAAV-TBG-MCS-NULL	P-AAVV-B68-Kan	pGMAAV-TBG-MCS-NULL (Kan resistance)
P-AAVV-B69	pGMAAV-CMV-circ-EF1-ZsGreen	P-AAVV-B69-Kan	pGMAAV-CMV-circ-EF1-ZsGreen (Kan resistance)
P-AAVV-B70	pGMAAV-CMV-MCS-T2Am-ZsGreen	P-AAVV-B70-Kan	pGMAAV-CMV-MCS-T2Am-ZsGreen (Kan resistance)

GM Multi-Serotype AAV Vector System



INDKan™ Industry-Used AAV Vector System

Product list of AAV expression plasmids (Amp and Kanamycin)

Cat.No	Products Name	Cat.No	Products Name
P-AAVV-B71	pGMAAV-CMV-MCS-3flag	P-AAVV-B71-Kan	pGMAAV-CMV-MCS-3flag (Kan resistance)
P-AAVV-B72	pGMAAV-GFAP-MCS-NULL	P-AAVV-B72-Kan	pGMAAV-GFAP-MCS-NULL (Kan resistance)
P-AAVV-B73	pGMAAV-cTNT-mCherry	P-AAVV-B73-Kan	pGMAAV-cTNT-mCherry (Kan resistance)
P-AAVV-B74	pGMAAV-U6-MCS-CMV-eRFP	P-AAVV-B74-Kan	pGMAAV-U6-MCS-CMV-eRFP (Kan resistance)
P-AAVV-B75	pGMAAV-CMV-MCS-EF1-eRFP	P-AAVV-B75-Kan	pGMAAV-CMV-MCS-EF1-eRFP (Kan resistance)
P-AAVV-B76	pGMAAV-CMV-MCS-3flag-T2A-eRFP	P-AAVV-B76-Kan	pGMAAV-CMV-MCS-3flag-T2A-eRFP (Kan resistance)
P-AAVV-B77	pGMAAV-hsyn-DIO-MCS	P-AAVV-B77-Kan	pGMAAV-hsyn-DIO-MCS (Kan resistance)
P-AAVV-B78	pGMAAV-U6-DIO-CMV-mcherry	P-AAVV-B78-Kan	pGMAAV-U6-DIO-CMV-mcherry (Kan resistance)
P-AAVV-B79	pGMAAV-CMV-T2A-ZsGreen-W3-BGH pa	P-AAVV-B79-Kan	pGMAAV-CMV-T2A-ZsGreen-W3-BGH pa (Kan resistance)
P-AAVV-B80	pGMAAV-cTNT-LUCi	P-AAVV-B80-Kan	pGMAAV-cTNT-LUCi (Kan resistance)
P-AAVV-B81	pGMAAV-U6-DIO-CMV-EGFP	P-AAVV-B81-Kan	pGMAAV-U6-DIO-CMV-EGFP (Kan resistance)
P-AAVV-B82	pGMAAV-CMV-3flag-EF1-ZsGreen-w3-bgh pa	P-AAVV-B82-Kan	pGMAAV-CMV-3flag-EF1-ZsGreen-w3-bgh pa (Kan resistance)
P-AAVV-B83	pGMAAV-CMV-MCS-EF1-luc	P-AAVV-B83-Kan	pGMAAV-CMV-MCS-EF1-luc (Kan resistance)
P-AAVV-B84	pGMAAV-TBG-P2A-LUCi	P-AAVV-B84-Kan	pGMAAV-TBG-P2A-LUCi (Kan resistance)
P-AAVV-B85	pGMAAV-CMV-MCS-3flag-IRES-hrGFP	P-AAVV-B85-Kan	pGMAAV-CMV-MCS-3flag-IRES-hrGFP (Kan resistance)
P-AAVV-B86	pGMAAV-GFAP-MCS-T2A-ZsGreen	P-AAVV-B86-Kan	pGMAAV-GFAP-MCS-T2A-ZsGreen (Kan resistance)

GM Multi-Serotype AAV Vector System

Different AAV Serotypes-based EGFP expression in mouse muscle and lung tissue



GM Promise™ ORF Viral Library

Discover the largest collection of ORF/cDNA expression clones from different species, including human, mouse, rat, and more with GeneMedi's Promise™-ORF. Our collection of ORFs expression clones come in verified mammalian or viral vectors (lentivirus, AAV, and adenovirus) and our Promise™-ORF viral-ready expression vectors make it easy for you to improve viral vector packaging efficiency or directly transfect mammalian cells, resulting in stronger and easier expression detection.

Product List [Click Here](#)

[Home](#) / [Gene Therapy products](#)

Promise-ORF™ viral CDNA library: Sequence-verified ORF/CDNA clones in lentivirus (lentiviral ORF clones), AAV, adenovirus and mammalian expression vectors.

Promise-ORF™

Discover the largest collection of ORF/cDNA expression clones from different species, including human, mouse, rat, and more with GeneMedi's Promise-ORF™. Our collection of ORFs expression clones come in verified mammalian or viral vectors (lentivirus, AAV, and adenovirus) and our Promise-ORF™ viral-ready expression vectors make it easy for you to improve viral vector packaging efficiency or directly transfect mammalian cells, resulting in stronger and easier expression detection.

gene id, gene name or alias, accession number(NM), Cat#

Product Type: Please Select

Catalog No.	Product Name	Gene Name & ...	Species	Accession Nu...	Marker	Fusion Tag	Promoter	Type	Detail
pGMLP000001	Human PEG10 Lentivirus plasmid	PEG10;EDR,HB-1,Mar2,Mart2,MEF	Human	NM_001040152	ZsGreen	3xflag (C-Terminal)	CMV	Lentivirus plasmid	Inquiry Details
pGMLP000002	Human SELENOM Lentivirus plasmid	SELENOM;SELM,SE	Human	NM_080430	ZsGreen	3xflag (C-Terminal)	CMV	Lentivirus plasmid	Inquiry Details
pGMLP000003	Human SELENOW Lentivirus plasmid	SELENOW;selW,SEI	Human	NM_003009	ZsGreen	3xflag (C-Terminal)	CMV	Lentivirus plasmid	Inquiry Details


Part 2 Solution for Cell Therapy Development

Solid-CD™ Flow Cytometry Antibodies (Naked/PE/APC/FITC)&Cell Isolation Beads

Product list

Cat.No	Products Name
GM-Tg-hg-T87075-Ab-1-PE250	Anti-Human CD3E monoclonal antibody (mAb) (PE)
GM-Tg-hg-T87075-Ab-1-FITC250	Anti-Human CD3E monoclonal antibody (mAb) (FITC)
GM-Tg-hg-T87075-Ab-1-APC250	Anti-Human CD3E monoclonal antibody (mAb) (APC)
GM-Tg-hg-T10191-Ab-1-PE250	Anti-Human CD4 monoclonal antibody (mAb) (PE)
GM-Tg-hg-T10191-Ab-1-FITC250	Anti-Human CD4 monoclonal antibody (mAb) (FITC)
GM-Tg-hg-T10191-Ab-1-APC250	Anti-Human CD4 monoclonal antibody (mAb) (APC)
GM-Tg-hg-T10191-Ab-2-PE250	Anti-Human CD4 monoclonal antibody (mAb) (PE)
GM-Tg-hg-T10191-Ab-2-FITC250	Anti-Human CD4 monoclonal antibody (mAb) (FITC)
GM-Tg-hg-T10191-Ab-2-APC250	Anti-Human CD4 monoclonal antibody (mAb) (APC)
GM-Tg-hg-TA040-Ab-1-PE250	Anti-Human CD8 monoclonal antibody (mAb) (PE)
GM-Tg-hg-TA040-Ab-1-FITC250	Anti-Human CD8 monoclonal antibody (mAb) (FITC)
GM-Tg-hg-TA040-Ab-1-APC250	Anti-Human CD8 monoclonal antibody (mAb) (APC)
GM-Tg-hg-T23212-Ab-1-PE250	Anti-Human CD14 monoclonal antibody (mAb) (PE)
GM-Tg-hg-T23212-Ab-1-FITC250	Anti-Human CD14 monoclonal antibody (mAb) (FITC)
GM-Tg-hg-T23212-Ab-1-APC250	Anti-Human CD14 monoclonal antibody (mAb) (APC)
GM-Tg-hg-T56365-Ab-1-PE250	Anti-Human CD19 monoclonal antibody (mAb) (PE)
GM-Tg-hg-T56365-Ab-1-FITC250	Anti-Human CD19 monoclonal antibody (mAb) (FITC)
GM-Tg-hg-T56365-Ab-1-APC250	Anti-Human CD19 monoclonal antibody (mAb) (APC)
GM-Tg-hg-T86323-Ab-1-PE250	Anti-Human NCAM1(CD56)monoclonal antibody (mAb) (PE)
GM-Tg-hg-T86323-Ab-1-FITC250	Anti-Human NCAM1(CD56)monoclonal antibody (mAb) (FITC)
GM-Tg-hg-T86323-Ab-1-APC250	Anti-Human NCAM1(CD56)monoclonal antibody (mAb) (APC)

Solid-CD™ Flow Cytometry Antibodies (Naked/PE/APC/FITC)&Cell Isolation Beads




Conclusion:
GeneMedi's Anti-Human CD3E antibody, Anti-Human CD4 antibody, Anti-Human CD8 antibody, Anti-Human CD14 antibody, Anti-Human CD19 antibody, Anti-Human NCAM1 (CD56) antibody, Anti-Human CD45 antibody, Anti-Human CEAM8/ CEACAM8/ CD66b antibody, and Anti-Human CD34 antibody are validated to detect PBMC-derived specific cell types by flow cytometry.

Cat No	Product Name
GM-Tg-hg-MP0250-Ab-3	Anti-Human CEAM8/ CEACAM8/ CD66b monoclonal antibody
GM-Tg-hg-T66426-Ab-3	Anti-Human CD34 monoclonal antibody
GM-Tg-hg-T66426-Ab-4	Anti-Human CD34 monoclonal antibody
GM-Tg-hg-T66426-Ab-7	Anti-Human CD34 monoclonal antibody
GM-Tg-hg-T66426-Ab-8	Anti-Human CD34 monoclonal antibody
GM-Tg-hg-T86323-Ab-1	Anti-Human NCAM1 (CD56) monoclonal antibody(mAb)
GM-Tg-hg-T23212-Ab-1	Anti-Human CD14 monoclonal antibody(mAb)
GM-Tg-hg-T56365-Ab-1	Anti-Human CD19 monoclonal antibody(mAb)
GM-Tg-hg-T87075-Ab-1	Anti-Human CD3E monoclonal antibody(mAb)
GM-Tg-hg-T10191-Ab-1	Anti-Human CD4 monoclonal antibody(mAb)
GM-Tg-hg-T10191-Ab-2	Anti-Human CD4 monoclonal antibody(mAb)
GM-Tg-hg-TA040-Ab-1	Anti-Human CD8 monoclonal antibody(mAb)
GM-Tg-hg-T43115-Ab-4	Anti-Human CD45 monoclonal antibody(mAb)

Solid-Iso™ Immunocytes Cell Isolation Kits & Beads

GeneMedi (GM) provides various cytokines for applications such as cell culture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.



Part 2 Solution for Cell Therapy Development

CAR-T Cell Preparation-Lentivirus Packaging Service and Products

Product list


CAR-X Ready-to-use Lentivirus

Cat.No	Products Name	Description
GMV-LVc-CD19	CD19 CAR Lentivirus	Our CD19 CAR Lentivirus is specifically designed to target CD19, a critical marker of B-cell malignancies. This vector is a cornerstone in the treatment of various leukemias and lymphomas, offering a beacon of hope for patients battling these cancers.
GMV-LVc-CD20	CD20 CAR Lentivirus	Targeting CD20-positive malignancies, our CD20 CAR Lentivirus is engineered to facilitate groundbreaking treatments against conditions such as non-Hodgkin lymphoma and chronic lymphocytic leukemia, showcasing our commitment to combating hematological cancers.
GMV-LVc-Her2	Her2 CAR Lentivirus	Our Her2 CAR Lentivirus targets the Her2 protein, offering a strategic approach to treating Her2-positive breast cancer. This vector embodies our dedication to advancing precision medicine and providing targeted therapies for patients with breast cancer.
GMV-LVc-BCMA	BCMA CAR Lentivirus	Focused on BCMA, a protein implicated in the pathogenesis of multiple myeloma, our BCMA CAR Lentivirus underscores our commitment to addressing this challenging condition with targeted therapeutic strategies.
GMV-LVc-GPC3	GPC3 CAR Lentivirus	By targeting GPC3, associated with hepatocellular carcinoma, our GPC3 CAR Lentivirus reflects our dedication to pioneering treatments for hard-to-treat cancers, emphasizing our innovative approach to cancer therapy.

CAR-X Analytical Tools


Cat.No	Products Name	Description
GTU-ADA-FMC63-Ab01-PE250	Anti-FMC63 mAb(PE)	Specifically targeting the FMC63 scFv used in CD19 CAR constructs, this antibody plays a crucial role in assessing the specificity and functionality of CD19-directed CAR-T cells, highlighting our focus on delivering precision in CAR-T cell therapy.
GTU-ADA-FMC63-Ab01-FITC250	Anti-FMC63 mAb(FITC)	
GTU-ADA-FMC63-Ab01-APC250	Anti-FMC63 mAb(APC)	
GTU-ADA-FMC63-Ab02-PE250	Anti-FMC63 mAb(PE)	
GTU-ADA-FMC63-Ab02-FITC250	Anti-FMC63 mAb(FITC)	
GTU-ADA-FMC63-Ab02-APC250	Anti-FMC63 mAb(APC)	This antibody is expertly crafted to detect the G4S linker within CAR constructs, providing a reliable tool for monitoring CAR expression and ensuring the efficacy of CAR-T cell therapies.
GMLS-Tag003-Ab01-PE250	Anti-(G4S)n mAb(PE)	
GMLS-Tag003-Ab01-FITC250	Anti-(G4S)n mAb(FITC)	
GMLS-Tag003-Ab01-APC250	Anti-(G4S)n mAb(APC)	Designed to recognize VHH1 domains, this antibody is a pivotal tool in the detection and analysis of CAR constructs that incorporate VHH1 domains. It offers a highly specific and sensitive means of verifying the presence and functionality of these innovative CAR constructs.
GMLS-Tag002-Ab01-PE250	Anti-VHH mAb(PE)	
GMLS-Tag002-Ab01-FITC250	Anti-VHH mAb(FITC)	
GMLS-Tag002-Ab01-APC250	Anti-VHH mAb(APC)	

CAR-T Products Validation data




	Name of GMLV-CAR	CAR Structure	Cassette	G4S Linker	FMC63	EGFP
1	Lenti-CAR-CD19-S1-EGFP-Puro	CD19 SCFV (FMC63)-CD8-4-1BB-CD3 ζ -EGFP-Puromycin;	LV-EF1-CAR-P2A-EGFP-T2A-Puromycin	Y	Y	Y
2	Lenti-CAR-CD19-S2-EGFP-Puro	CD19 SCFV (FMC63)-CD28-CD3 ζ -EGFP-Puromycin;	LV-EF1-CAR-P2A-EGFP-T2A-Puromycin	N	Y	Y
3	Lenti-CAR-CD19-S3-EGFP-Puro	CD19 SCFV (FMC63)-CD8-CD28-4-1BB-CD3 ζ -EGFP-Puromycin,	LV-EF1-CAR-P2A-EGFP-T2A-Puromycin	Y	Y	Y
4	GMLV-EF1-MCS-P2A-EGFP-T2A-PURO	Null	LV-EF1-MCS-P2A-EGFP-T2A-Puromycin	N	N	Y
5	Lenti-CAR-CD19-S1-Puro	CD19 SCFV (FMC63)-CD8-4-1BB-CD3 ζ -Puromycin;	LV-EF1-CAR-P2A-Puromycin	Y	Y	N
6	Lenti-CAR-CD19-S2-Puro	CD19 SCFV (FMC63)-CD28-CD3 ζ -Puromycin;	LV-EF1-CAR-P2A-Puromycin	N	Y	N
7	Lenti-CAR-CD19-S3-Puro	CD19 SCFV (FMC63)-CD8-CD28-4-1BB-CD3 ζ -Puromycin,	LV-EF1-CAR-P2A-Puromycin	Y	Y	N
8	GMLV-EF1-MCS-P2A-Puro	Null	LV-EF1-MCS-P2A-Puromycin	N	N	N
9	Blank	Null	Null	N	N	N

Figure 1. GM-Lenti-CAR Lentivirus represent a great performance in CAR-expression



The GMLS-Tag003-Ab-1 (Anti-G4S linker monoclonal antibody) represent a similar ratio to antigen-specific CAR detection in CAR-T cells

Figure 2. The GTU-ADA-FMC63-Ab01 and GMLS-Tag003-Ab-1 are validated to detect CAR-NK cells.



Donor 1: GTU-ADA-FMC63-Ab01 VS Company X

Figure 3. The GTU-ADA-FMC63-Ab01 is validated to detect Simulate samples of CAR-NK infusion in patients.




Figure 4. For detecting CAR-T cells, GeneMedi's GMLS-Tag003-Ab-1 detection background is lower, and the detection results are closer to specific antigen detection, compared to Company C.

Part 3 Platform & Service

GM AAV packaging services

Platform	AAV Manufacturing Capacity	AAV9 Yield	AAV8 Yield	AAV5 Yield	AAV2 Yield	AAV PHP.eB Yield
293T suspension cells	~ 20L	4.7E+13VG/L	1.9E+13VG/L	2.3E+13VG/L	5.4E+12VG/L	1.1E+13VG/L
- All common-used serotypes: AAV1, AAV2, AAV5, AAV6, AAV8, AAV9, AAVrh10, AAV-DJ, AAV.PHP, AAV-Anc80 etc. - ssAAV, scAAV - Customized AAV capsid and vectors						




Figure 1: Consistent AAV Production Platform With High Yield.





Figure 2: Manufacturing Batch Stability of Different AAV Serotypes

G-NEXT - Novel AAV Development Platform




Strategy of G-NEXT™ AAV Development


G-NEXT™ combines AAV biology, hiPSC models, structure-based engineering, and high-throughput manufacturing to advance the development of the next generation of AAV-based therapies.

Rational novel targeting AAV development

Drawbacks in conventional AAV vectors




Traditional development of targeting AAV vectors



- Animal model cannot fully simulate human organs
- Highly random
- Heavy workload

Rational novel targeting AAV development

Rational novel targeting AAV development



- Ligand-receptor mediated infection
- Modified surface of AAV partical
- Modular construction
- Easily extensible in targeting

Higher targeting efficacy compare with wt-AAV

